BioCentury
ARTICLE | Company News

Two approvals boost Baxalta's hemophilia business

November 14, 2015 1:56 AM UTC

Two hemophilia A treatments from Baxalta Inc. (NYSE:BXLT) were approved on Friday, one each in the U.S. and EU, as the company faces increasing pressure on its hemophilia franchise.

FDA approved a BLA for Adynovate ( BAX 855) to prevent and control bleeding episodes in patients aged 12 and older with hemophilia A, and the European Commission approved an MAA for Obizur susoctocog alfa to treat bleeding episodes in adults with acquired hemophilia A caused by antibodies to Factor VIII. ...